ARGININE DEIMINASE WITH REDUCED CROSS-REACTIVITY TOWARD ADI-PEG 20 ANTIBODIES FOR CANCER TREATMENT

• Main Authors: CHEN LIANG, JAMES A THOMSON, LI YAN, ROBERT ALMASSY, WES SISSON, SHIA WEI-JONG, RICHARD SHOWALTER
• Format: Patent
• Language: English; Japanese
• Published: 14.01.2021
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

To provide arginine deiminase with reduced cross-reactivity toward ADI-PEG 20 antibodies for cancer treatment.SOLUTION: The present invention relates generally to: isolated arginine deiminase (ADI) proteins which have reduced cross-reactivity with anti-ADI-PEG 20 antibodies compared to ADI-PEG 20, but which can have functional characteristics comparable to or better than ADI-PEG 20; compositions comprising the ADI proteins; and related methods of treating arginine-dependent diseases or related diseases such as cancer. Embodiments of the present invention relate to selected ADI enzymes, which, in some embodiments, are conjugated with PEG through a linker, e.g., a stable linker.SELECTED DRAWING: None 【課題】癌治療のためのＡＤＩ−ＰＥＧ２０抗体に対する交差反応性が低減したアルギニンデイミナーゼの提供。【解決手段】本発明は、一般的に、ＡＤＩ−ＰＥＧ２０に比べて抗ＡＤＩ−ＰＥＧ２０抗体との低減した交差反応性を有するが、ＡＤＩ−ＰＥＧ２０に匹敵するかまたはより良い機能特性を有し得る単離アルギニンデイミナーゼ（ＡＤＩ）タンパク質、該ＡＤＩタンパク質を含む組成物、及び癌などのアルギニン依存性疾患または関連疾患を治療する関連方法に関する。本発明の実施形態は、選択ＡＤＩ酵素に関し、一部の実施形態において、リンカー、例えば、安定リンカーを介してＰＥＧと結合している。【選択図】なし